Frank Griesinger, MD, PhD from the Pius-Hospital Oldenburg, Oldenburg, Germany discusses progress in the development of a German clinical research platform. The platform started a year ago and aims to prospectively capture in-depth data including clinical characteristics, health insurance, socio-economic factors, patient outcomes and quality of life. Around 10,000 patients were recruited into this registry which also include data from a bio bank and a tissue repository with clinically annotated material. According to Dr. Griesinger, this is a very important study that will allow to analyse how patients are treated in Germany, and to identify correlations between molecular, clinical and other socio-economic factors. Experts will also be able to correlate new biomarkers with clinical outcomes. Dr. Griesinger believes that future improvements will be apparent for treatment, diagnostics and access to clinical trials in Germany. Recorded at the 2016 World Congress of Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) in Vienna, Austria.